

Accepted Manuscript

Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents

Shashi Pandey, Pooja Agarwal, Kumkum Srivastava, S. RajaKumar, Sunil K. Puri, Pravesh Verma, J.K. Saxena, Abhisheak Sharma, Jawahar Lal, Prem. M.S. Chauhan



PII: S0223-5234(13)00332-2

DOI: [10.1016/j.ejmech.2013.05.023](https://doi.org/10.1016/j.ejmech.2013.05.023)

Reference: EJMECH 6201

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 15 February 2013

Revised Date: 30 April 2013

Accepted Date: 19 May 2013

Please cite this article as: S. Pandey, P. Agarwal, K. Srivastava, S. RajaKumar, S.K. Puri, P. Verma, J.K. Saxena, A. Sharma, J. Lal, P.M.S. Chauhan, Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents, *European Journal of Medicinal Chemistry* (2013), doi: 10.1016/j.ejmech.2013.05.023.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical abstract:

Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents


Shashi Pandey^a, Pooja Agarwal^b, Kumkum Srivastava^b, S. RajaKumar^b, Sunil K. Puri^b, Pravesh Verma^c, J. K. Saxena^c, Abhisheak Sharma^d, Jawahar Lal^d and Prem. M. S. Chauhan^{a, *}

^a Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^b Parasitology Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^c Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^d Pharmacokinetics and Metabolism Division CSIR-Central Drug Research Institute, Lucknow 226001, India



Series of novel 4-aminoquinoline-tetrazole derivatives were synthesized. Most of compounds exhibited potent activity against resistant strain (K1). Compounds **20** and **23** also showed *in vivo* suppression of 99.99% parasitaemia on day 4.

Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents

Shashi Pandey^a, Pooja Agarwal^b, Kumkum Srivastava^b, S. RajaKumar^b, Sunil K. Puri^b, Pravesh Verma^c, J. K. Saxena^c, Abhisheak Sharma^d, Jawahar Lal^d and Prem. M. S. Chauhan^{a,*}

^a Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^b Parasitology Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^c Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^d Pharmacokinetics and Metabolism Division CSIR-Central Drug Research Institute, Lucknow 226001, India

Abstract: A series of novel tetrazole derivatives of 4-aminoquinoline were synthesized and screened for their antimalarial activities against both chloroquine-sensitive (3D7) and chloroquine-resistant (K1) strains of *Plasmodium falciparum* as well as for cytotoxicity against VERO cell lines. Most of the synthesized compounds exhibited potent antimalarial activity as compared to chloroquine against K1-strain. Compounds with significant *in vitro* antimalarial activity were then evaluated for their *in vivo* efficacy in Swiss mice against *P. yoelii* following both intraperitoneal (ip) and oral administration, wherein compounds **20** and **23** each showed *in vivo* suppression of 99.99% parasitaemia on day 4.

Keywords: 4-Aminoquinoline, Chloroquine, Tetrazole, Antimalarial, Cytotoxicity.

*Corresponding author. Tel.: +91 522 2612411; fax: +91 522 2623405

e-mail addresses: prem_chauhan_2000@yahoo.com; prem58@hotmail.com

1. Introduction

Parasitic diseases are a global problem, affecting 30% of the world's population. Among parasitic diseases, Malaria is one of the most devastating infectious disease claiming more lives than any other parasitic infections. There were at least 216 million cases of acute malaria reported in 2010 and about 655, 000 people died from malaria, 86% of which are children under 5 years of age [1]. It is most common in tropical and subtropical areas and 90% of all cases are found in sub-Saharan Africa. These facts are attributable almost exclusively to *Plasmodium falciparum*, one of the five *Plasmodium* species responsible for malaria in humans.

Since the development of quinine, drugs with quinoline scaffold have immense significance as antimalarial chemotherapeutic agents. Among the quinoline derivatives, 4-aminoquinolines (Figure 1) especially Chloroquine (CQ, 1) have been extensively utilized for the treatment of malaria [2]. However, the widespread resistance of *P. falciparum* to chloroquine and other existing antimalarial drugs including the recent artemisinin class of antimalarial has hampered the efforts to combat this deadly disease [3-6]. So, there is an urgent need for the development of new antimalarial agents active against drug-resistant malaria strains. However, despite the development of resistance, CQ is still attractive pharmacophore for chemical modification, owing its excellent clinical efficacy, limited host toxicity, ease to use, simple cost-effective synthesis [7]. Furthermore, literature survey on 4-aminoquinoline antimalarials clearly suggested that antimalarial activity, particularly, inhibition of β -hematin formation and accumulation of the drug at the target site, resides in 4-aminoquinoline core [8]. In the past two decades, a number of new 4-aminoquinoline analogues with enhanced activity against CQR strains were developed by synthetic modifications of the CQ side chain [9-12]. Consequently, researches regarding the exploration of novel 4-aminoquinoline analogues that are equally active against chloroquine

sensitive (CQ-S) and chloroquine resistant (CQ-R) strains has received much attention during recent years.

4-aminoquinoline hybridization is another quite attractive strategy which has been recently introduced in medicinal chemistry and drug discovery process, in order to circumvent the problem of antimalarial drug resistance [13-17]. Moreover, in recent years, incorporation of other functionalities in the side chain of 4-aminoquinoline emerged as promising strategies to construct the molecules with enhanced activity against drug-resistant *P. falciparum* and also with improved metabolic stability.

Recently, Campiani et al. synthesized Clotrimazole (CLT) analogues [18] and subsequently prepared hybrid of the 4-aminoquinoline with the clotrimazole-like pharmacophore [19] in which imidazole ring of CLT behaves as a Fe(III) axial ligand and inhibit β -hematin formation and reported promising *in vitro* (against both sensitive and resistant strain) and *in vivo* antimalarial activities. On the other hand, tetrazole based compounds have received attention due to their wide range of biological activities [20-24]. Moreover, various tetrazole-based compounds have also shown good coordination properties and are able to form stable complexes with several metal ions inhibitors [25]. Recently, Roman et al. had exploited the ability of the tetrazole ring to coordinate with the iron centre of heme in the design of heme oxygenase inhibitors [26].

Inspired by these encouraging results, we envisaged that incorporation of tetrazole moiety (with ability to coordinate with the heme) in the side chain of 4-aminoquinoline pharmacophore would lead to develop the new antimalarial agents active against chloroquine resistant strains (CQ-R) of *P. falciparum*. On the basis of the above fact and in the continuation of our ongoing programme to develop new potent antimalarial agents [27-30] we herein, report the efficient synthesis of new 4-aminoquinoline analogues containing tetrazole moiety (Figure 2) and there evaluation as potentially active compounds against *Plasmodium* malaria parasite.

2. Results and Discussion

2.1. Chemistry

The targeted compounds were synthesized *via* two-step simple and efficient synthetic protocol. The detailed synthetic route for the synthesis of intermediate **(7-10)** and target compounds **(11-32)** is outlined in scheme 1. Reaction of commercially available 4, 7-dichloroquinoline with corresponding diaminoalkanes/piperazine/p-phenylenediamine *via ipso* nucleophilic substitution reaction resulted in the formation of compounds **(7-10)**. These intermediate compounds **(7-10)** were then utilized as amine input in isocyanide based multicomponent reaction. The target compounds **(11-32)** were efficiently prepared by treating commercially available aldehyde with amine **(7-10)** corresponding isocyanide and TMSN₃ in methanol at room temperature. All compounds were characterized using ¹H NMR, ¹³C NMR, HRMS and IR spectroscopy.

2.2. Biological assay

All the synthesized target compounds **(11-32)** were screened for their *in vitro* antimalarial activity against CQ sensitive 3D7 strain and CQ-resistant K1 strain of *P. falciparum* (Table-1) using a standardized inexpensive assay based on Malaria SYBR Green I nucleic acid staining dye based fluorescence (MSF) assay. The IC₅₀ values were calculated from experiments carried out in triplicate. The cytotoxicity of all the synthesized molecules was determined against VERO cell line using MTT assay. The *in vivo* drug responses of selected compounds were evaluated in swiss mice infected with resistant strain N-67 of *P. yoelii* which is intrinsically resistant to CQ.

2.2.1 *In vitro* antimalarial activity

Initially, all the synthesized 4-aminoquinoline-tetrazole derivatives **(11-32)** were evaluated for their *in vitro* antimalarial efficacy against CQ-sensitive (3D7) and CQ-resistant (K1) strains of *P. falciparum*. All tested compounds exhibited moderate activity against the CQ-S (3D7) strain,

with IC_{50} value ranging from 10.66 to 216 nM. Among these 22 compounds, 3 compounds (**20**, **21** and **23**) showed promising activity 10.66, 11.01, 11.78 nM respectively, 11 compounds displayed moderate activity with the IC_{50} values ranging from 23.89 nM to 81.40 nM. Furthermore, 13 compounds were found to be more active (with IC_{50} values between 73.70 and 233.70 nM) than CQ (IC_{50} = 254 nM), when screened against CQ-R (K1) strain of *P. falciparum*. Two compounds **11** and **17** showed IC_{50} values 277.80 and 383.50 nM which was comparable to CQ. Moreover, some of our synthesized compounds were also showing low resistance index (Table-1).

The structure-activity relationship studies on these compounds suggested that the activity of these compounds were greatly influenced by type of linker, substitutions on aromatic ring as well as substitution in the tetrazole ring. The activity data suggested that the type of linker had a remarkable influence on the activity of 4-aminoquinoline tetrazole derivatives. According to our results, compounds with ethylene diamine linker (**11**, **12**) exhibited mild inhibition against 3D7 strain in comparison to standard drug. However, the activity decreases dramatically on increasing the chain length to 3 carbon (**13-15**). Interestingly, substitution of the flexible aliphatic linker with rigid aromatic linker p-phenylene diamine resulted in manifold increased activity against both the strains (3D7, K1). This increased activity may be due to increase in lipophilicity of phenylene linker. Moreover, among the synthesized series, compound **25**, **27** and **30** with phenylenediamine linker were found to be most active against resistant strain (K1) and were 3.44-3.38 fold more active than chloroquine. These SAR data clearly suggested that aromatic linker have crucial role in activity of the compounds and analogues with aromatic linker probably endowed with new leads that overcome drug resistance.

Another modification performed in the series was substitution of *tert* butyl group in tetrazole ring with cyclohexyl ring. The cyclohexyl substituted analogues **28-30** showed manifold decrease in

potency than analogues having *tert* butyl **18**, **20** and **23** against 3D7 strain. Nevertheless, against K1 strain, 4-chloro **28** and 4-bromo **29** analogue with cyclohexyl substituted tetrazole ring showed increased activity while 3, 4 dimethoxy **30** resulted in decreased activity as compared to respective analogue with *tert* butyl substituted tetrazole ring.

Furthermore, the activity of compounds also depends on the substitution on phenyl ring however there is no obvious trend of activity with respect to substituted group and strains of parasite. Compounds with unsubstituted phenyl ring **24** and 4-ethyl substituted group **26** were showing mild activity IC_{50} 59.64, 51.35 nM respectively against 3D7 strain but none of compounds were active against resistant strain K1, while 4-methyl substituted analogue **25** was found to be inactive against 3D7 strain but found to be most potent in series against resistant strain with IC_{50} value 75.39 nM. Interestingly, despite the type of linker naphthalene substituted derivatives were found to be active against K1 strain wherein compound **27** showed promising activity with IC_{50} 77.79 nM and also showed better activity in 3D7 strain IC_{50} 28.00 nM. In case of methoxy substituted compounds, 4-methoxy, 3, 4-dimethoxy and 3, 4, 5 trimethoxy derivatives were showing good activity in sensitive strain (3D7) and showed mild activity in resistant strain except 3, 4 dimethoxy compounds which exhibited promising activity against CQ-R strain with IC_{50} 76.16 nM. Introduction of halogen substituent have immense influence on activity. Compounds substituted with 4-chloro **20** and 4-bromo **23** on phenyl ring were found to be most active against 3D7 strain and have very promising activity against K1 strain while 4-fluoro **22** substituted analogue showed mild activity against 3D7 and found to be inactive against K1. Additionally analogue **20** and **23** were also found to be *in vivo* active.

Additionally, ferrocene containing heterocyclic compounds gaining interest because of their wide applicability in organic, organometallic synthesis as well as in medicinal chemistry. [31-34]

More precisely, the successful development of Ferroquine, Trioxaferroquines and ferrocenyl derivative of Ciprofloxacin as antimalarial drugs having strong antimalarial activity against resistant strain of *plasmodium* as compared to parent drug inspired us to synthesize ferrocene containing analogues **31** and **32**. However, disappointingly in our case these analogues were not found to be active.

2.2.2 *In vitro* cytotoxicity

The cytotoxicity of all the synthesized molecules **11-32** was determined against VERO cell line using MTT assay (Table 1). 17 molecules showed high selectivity index (SI) ranging between 182.96 and 7076.29, rest of molecules showed selectivity index <100 but not less than 49.73. Compounds **20**, **21** and **23** which were most potent against 3D7 also showed good selectivity index 4616.14, 7076.29 and 2332.43 respectively (Table-1). Compound **30** which was most potent against resistant strain K1, also showed good selectivity index of 1191.58. In general, most of the compounds of the series exhibited reasonably promising activity against K1 strain, less cytotoxic effect with fairly high selectivity index, and consequently these 4-aminoquinoline tetrazole derivatives are good candidate for further lead optimization.

2.2.3 β -Hematin inhibitory activity

To find out the mode of action of the synthesized molecules, the β -hematin inhibitory activity of all the molecules was carried out (Table 2). All of the screened compounds inhibited β -hematin formation in a concentration-dependent manner. All the tested compound showed IC_{50} values between 3.81 μ g/mL and 6.33 μ g/mL. Among these, compound **29** showed better activity with IC_{50} values = 3.81 μ g/mL than CQ (3.95 μ g/mL).

2.2.4 *In vivo* antimalarial activity

Compounds with significant activity *in vitro* (**16**, **18**, **20**, **21**, **23**, **25**, **27**, **29** and **30**) were selected for *in vivo* activity in Swiss mice against with CQR N-67 strain of *P. yoelli*. Initially the *in vivo* activity of selected molecules was determined through intraperitoneal route at the dose of 50 mg/kg administered once daily for four consecutive days and monitored for parasitemia, and survival of mice until day 28 postinfection (Table 3). The compounds **20** and **23** exhibited 99.99 % parasitaemia suppression on day four, while compounds **16**, **21**, **27** and **30** suppressed parasitaemia by 73.91%, 71.49%, 57.03%, 69.56% respectively. Furthermore, these data clearly showed that halogen substituted phenyl derivatives have better *in vivo* activity profile. Compound **20**, one of the potent compound of the series, showed 99.99% parasitaemia suppression on day 4 and 60% survival on day 28 of treatment at a dose of 50 mg/kg $\times$ 4 days, while compound **23**, showed 99.99% parasite suppression on day 4 and 80% survival on day 28 of treatment. Furthermore, compound **20**, cured 60% of treated mice while compound **23**, cured 40% of treated mice. Compound **20** and **23**, with promising result by intraperitoneal route were further screened at 100 mg/ kg by oral route. Both compounds exhibited promising results with 99.99% parasite suppression on day 4, and 60% survival on day 28 of treatment.

2.2.5 Preliminary Pharmacokinetic Studies

The compelling *in vitro* and *in vivo* antimalarial activity exhibited by compound **20** and **23** encouraged us to perform *in vivo* oral pharmacokinetic study of compound **20** and **23**. Pharmacokinetic studies revealed that the animals tolerated the treatment as no peculiarities in the animals behavior were observed. Calculations of the pharmacokinetic data were based on the mean serum concentrations and were performed by the use of noncompartmental approaches using WinNonlin program, version 5.1 (Scientific Consulting Inc.). **20** and **23** were rapidly absorbed and slowly eliminated (Figure 3 and Table 4). Both compounds showed multiple peaks phenomenon which may be due to the enterohepatic recirculation, delayed gastric emptying, and

variability of absorption in different regions of gastrointestinal tract [35]. For both compound **20** and **23**, the volume of distribution (V_d , 28.6 L and 63.38 L, respectively) is greater than the total blood volume (13.5 ml; Davies and Morris, 1993), [36] indicating high extra-vascular distribution of the compound. Moreover, the systemic clearance of both **20** and **23** was higher than the hepatic blood flow of the rat (Davies and Morris, 1993) which indicates an extra-hepatic elimination. On comparison with reported pharmacokinetic profile of CQ, [37] compound **23** showed higher terminal half-life than CQ. Both compounds **20** and **23** have higher volume of distribution which indicates their extensive distribution in the body than that of CQ. A 1.9-fold lower clearance, 1.9-fold higher AUC and 3.3-fold higher MRT of **23** than that of **20** suggest that **23** could be a better candidate drug than **20**.

3. Conclusion

In summary, we have synthesized new tetrazole derivatives of 4-aminoquinoline by utilizing highly efficient TMSN₃-Ugi multicomponent reaction. The majority of these synthesized molecules exhibited promising *in vitro* antimalarial activity especially against CQ-R strain (K1). Most of the compounds have shown the fairly high selectivity index. In present series, Compound **20** and **23** showed promising *in vitro* activity against both CQ-S as well as CQ-R strain of *P. falciparum* and also excellent *in vivo* antimalarial activity against *P. yoelli*. Taken as a whole, these studies highlights the potential of these new 4-aminoquinolne-tetrazole derivatives especially compound **20** and **23** for developing novel antimalarials that address CQ resistance as well as able to reduce parasitaemia after oral administration.

4. Experimental Methods

4.1. General information

Commercially available reagents and solvents were used without further purification. Thin-layer chromatography (TLC) was carried out with silica gel plates (silica gel 60 F254), that were visualized by exposure to ultraviolet light. IR spectra were recorded on a FTIR spectrophotometer Shimadzu 8201 PC and are reported in terms of frequency of absorption (cm^{-1}). ^1H NMR and ^{13}C NMR spectra were recorded on Bruker Supercon Magnet Avance DRX-400, 300 or DPX 200 FT spectrometers using TMS as an internal reference and the samples were dissolved in suitable deuterated solvents (Chemical shifts (δ) are given in ppm relative to TMS and coupling constants (J) in Hz). HR-DART MS were recorded on JEOL, JMS T100LC Accu TOF. Column chromatography purifications were performed in flash using 60-120 or 100-200 mesh silica gel. The melting points were recorded on an electrically heated melting point apparatus and are uncorrected.

4.2 General procedure for the synthesis of compounds 7 and 8

A mixture of 4, 7-dichloroquinoline (1 equiv.) and 1, 2-diaminoethane/ 1, 3-diaminopropane (5 equiv.) were heated for 6-8 h with continued stirring to drive the reaction to completion. After completion of the reaction the excess solvent was removed under vacuum. The reaction mixture was then poured into ice cold water and precipitate was filtered and washed with ethyl acetate to furnish compound **7** and **8** in quantitative yields.

4.3 General procedure for the synthesis of compounds 9 and 10

A solution of 4, 7-dichloroquinoline (1 equiv.) and p-phenylenediamine/ piperazine (2.0 equiv.) in absolute ethanol was refluxed in presence of catalytic amount of *p*-TSA for 3-5 h. During the refluxing, precipitation of product occurred. The precipitate was collected through filtration, washed with ethanol and dried under vacuum to get the desired **9** and **10** in excellent yields.

4.4. General procedure for the synthesis of compounds 11–32

To a stirred solution of amine **7-10** (1mmol) in methanol (6 mL) were added successively commercially available benzaldehyde (1.1 mmol), isocyanide (1 mmol) and TMSN₃ (1 mmol). The mixture was stirred at room temperature for 24 h. After completion of the reaction, solvent was evaporated at reduced pressure and purified through column chromatography (eluent: CHCl₃/ MeOH) using 60-120 or 100-200 mesh silica gel to afford the desired products (**11-32**).

4.4.1. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(4-chlorophenyl)methyl)-*N*²-(7-chloroquinolin-4-yl)ethane-1,2-diamine (**11**)

White semi solid; Yield: 76 %; IR (cm⁻¹, KBr): 3269, 2954, 1581, 1434, 1234; ¹H NMR (300 MHz, CDCl₃): δ = 8.48 (d, 1H, *J* = 5.1 Hz), 8.04 (d, 1H, *J* = 8.8 Hz), 7.94 (s, 1H), 7.44 (d, 1H, *J* = 8.9 Hz), 7.34 (d, 2H, *J* = 7.9 Hz), 7.21 (d, 2H, *J* = 7.9 Hz), 6.37 (br s, 1H), 6.32 (d, 1H, *J* = 5.1 Hz), 5.37 (s, 1H), 3.34 (br s, 2H), 3.31-2.89 (m, 2H), 2.74 (br s, 1H), 1.60 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ = 155.3, 151.4, 150.2, 148.5, 136.8, 134.9, 134.7, 129.3, 127.9, 125.4, 122.2, 117.3, 98.8, 61.8, 58.3, 45.8, 42.5, 29.9; HRMS (ESI TOF (+)) calcd for [C₂₃H₂₅Cl₂N₇ + H⁺] 470.1621 found 470.1622.

4.4.2. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(naphthalen-1-yl)methyl)-*N*²-(7-chloroquinolin-4-yl)ethane-1,2-diamine (**12**)

White solid; Yield: 70 %; mp 115-116 °C; IR (cm⁻¹, KBr): 3370, 2977, 1587, 1235; ¹H NMR (300 MHz, CDCl₃): δ = 8.49 (d, 1H, *J* = 5.3 Hz), 8.23 (d, 1H, *J* = 8.0 Hz), 7.97-7.92 (m, 2H), 7.86 (d, 1H, *J* = 8.2 Hz), 7.79 (d, 1H, *J* = 8.9 Hz), 7.63-7.53 (m, 2H), 7.35-7.27 (m, 2H), 6.80 (d, 1H, *J* = 7.0 Hz), 6.38 (br s, 1H), 6.33 (d, 1H, *J* = 5.3 Hz), 6.18 (s, 1H), 3.49-3.38 (m, 2H), 3.29-3.13 (m, 2H), 1.51 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ = 155.4, 151.7, 150.0, 148.8, 134.8, 134.4, 134.2, 130.6, 129.7, 129.5, 128.2, 127.5, 126.2, 125.4, 125.1, 122.1, 122.0, 117.3, 98.9,

61.8, 55.5, 46.5, 42.3, 29.7; HRMS (ESI TOF (+)) calcd for $[C_{27}H_{28}ClN_7 + H^+]$ 486.2167 found 486.2167.

4.4.3 $N^1-((1\text{-tert-butyl-1H-tetrazol-5-yl})(4\text{-chlorophenyl})\text{methyl})\text{-}N^3\text{-(7-chloroquinolin-4-yl)propane-1,3-diamine (13)}$

White solid; Yield: 72 %; mp 130-132 °C; IR (cm^{-1} , KBr): 3432, 2988, 1636, 1455, 1217; ^1H NMR (300 MHz, CDCl_3): δ = 8.41 (d, 1H, J = 5.2 Hz), 7.88 (d, 1H, J = 1.7 Hz), 7.37-7.27 (m, 6H), 7.06 (dd, 1H, J = 1.8 Hz, J = 8.8 Hz), 6.29 (d, 1H, J = 5.5 Hz), 5.32 (s, 1H), 3.44 (br s, 2H), 2.92-2.78 (m, 3H), 1.94 (br s, 2H), 1.51 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ = 154.9, 150.7, 150.6, 147.7, 136.6, 135.1, 134.8, 129.5, 129.4, 127.2, 125.2, 122.0, 116.9, 98.1, 61.6, 58.6, 47.5, 43.4, 29.9, 27.3; HRMS (ESI TOF (+)) calcd for $[C_{24}H_{27}Cl_2N_7 + H^+]$ 484.1778 found 484.1782.

4.4.4 $N^1-((1\text{-tert-butyl-1H-tetrazol-5-yl})(\text{naphthalen-1-yl})\text{methyl})\text{-}N^3\text{-(7-chloroquinolin-4-yl)propane-1,3-diamine (14)}$

Off white solid Yield: 75 %; mp 68-70 °C; IR (cm^{-1} , KBr): 3269, 2830, 1580, 1371; ^1H NMR (300 MHz, $\text{DMSO-}d_6$): δ = 8.37-8.31 (m, 2H), 8.06 (d, 1H, J = 8.9 Hz), 7.97 (d, 1H, J = 8.2 Hz), 7.91 (d, 1H, J = 8.1 Hz), 7.77 (s, 1H), 7.54-7.51 (m, 2H), 7.45-7.39 (m, 2H), 7.29 (d, 1H, J = 9.8 Hz), 6.99 (d, 1H, J = 7.1 Hz), 6.43 (d, 1H, J = 5.3 Hz), 6.19 (s, 1H), 3.34 (br s, 2H), 2.84-2.79 (m, 2H), 1.86 (br s, 2H), 1.51 (s, 9H); ^{13}C NMR (75 MHz, $\text{DMSO-}d_6$) δ = 155.1, 151.2, 149.7, 148.3, 134.8, 133.1, 132.8, 130.3, 128.2, 128.1, 126.7, 126.2, 125.4, 124.7, 124.4, 123.4, 123.4, 123.0, 116.8, 98.1, 60.9, 54.1, 45.4, 28.6, 27.7 ; HRMS (ESI) calcd for HRMS (ESI TOF (+)) calcd for $[C_{28}H_{30}ClN_7 + H^+]$ 500.2324 found 500.2326.

4.4.5 $N^1-((1\text{-tert-butyl-1H-tetrazol-5-yl})(3,4\text{-dimethoxyphenyl})\text{methyl})\text{-}N^3\text{-(7-chloroquinolin-4-yl)propane-1,3-diamine (15)}$

White solid; Yield: 68%; mp 146-147 °C; IR (cm⁻¹, KBr): 3356, 2973, 1584, 1216; ¹H NMR (300 MHz, DMSO-*d*₆): δ = 8.43 (d, 1H, *J* = 5.8 Hz), 8.18 (d, 1H, *J* = 9.0 Hz), 7.8 (s, 1H), 7.46 (d, 1H, *J* = 8.9 Hz), 7.16 (s, 1H), 6.88 (s, 2H), 6.58 (d, 1H, *J* = 5.9 Hz), 5.42 (s, 1H), 3.71 (s, 3H), 3.68 (s, 3H), 3.39-3.35 (m, 2H), 2.62-2.58 (m, 2H), 1.86-1.83 (m, 2H), 1.62 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ = 156.0, 152.4, 148.8, 148.6, 147.9, 144.4, 135.4, 131.1, 125.2, 124.7, 123.8, 120.7, 116.5, 112.2, 111.5, 98.6, 61.4, 57.1, 55.6, 55.5, 45.2, 41.6, 29.4, 27.5; HRMS (ESI TOF (+)) calcd for [C₂₆H₃₂ClN₇O₂ + H⁺] 510.2379 found 510.2379.

4.4.6. *4-((1-tert-butyl-1H-tetrazol-5-yl)(4-chlorophenyl)methyl)piperazin-1-yl)-7-chloroquinoline (16)*

Off white solid Yield: 78 %; mp 200-210 °C; IR (cm⁻¹, KBr): 3421, 3018, 1575, 1493, 1215; ¹H NMR (300 MHz, CDCl₃): δ = 8.67 (d, 1H, *J* = 4.9 Hz), 8.05 (s, 1H), 7.89 (d, 1H, *J* = 8.9 Hz), 7.39-7.37 (m, 5H), 6.79 (d, 1H, *J* = 5.0 Hz), 5.44 (s, 1H), 3.23 (s, 4H), 3.08-3.05 (m, 2H), 2.74-2.71 (s, 2H), 1.72 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ = 156.6, 153.4, 151.8, 150.0, 134.8, 134.7, 133.4, 130.9, 128.9, 128.7, 126.0, 125.1, 121.7, 108.9, 64.1, 61.5, 52.2, 49.8, 30.2; HRMS (ESI TOF (+)) calcd for [C₂₅H₂₇Cl₂N₇ + H⁺] 496.1778 found 496.1782.

4.4.7. *N¹-((1-tert-butyl-1H-tetrazol-5-yl)(4-methoxyphenyl)methyl)-N⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (17)*

Yellow solid; Yield: 78 %; mp 106-107 °C; IR (cm⁻¹, KBr): 3269, 2954, 1581, 1434, 1234; ¹H NMR (300 MHz, CDCl₃): δ = 8.35 (d, 1H, *J* = 5.3 Hz), 7.92 (s, 1H), 7.79 (d, 1H, *J* = 8.8 Hz), 7.34 (d, 2H, *J* = 8.7 Hz), 7.19-7.17 (m, 3H), 7.04 (d, 2H, *J* = 8.3 Hz), 6.83 (d, 2H, *J* = 8.5 Hz), 6.64 (d, 2H, *J* = 8.4 Hz), 6.54 (d, 1H, *J* = 5.3 Hz), 6.03 (d, 1H, *J* = 9.2 Hz), 4.84 (d, 1H, *J* = 9.2 Hz), 3.73 (s, 3H), 1.62 (s, 9H); ¹³C NMR (50 MHz, CDCl₃) δ = 159.8, 155.3, 151.7, 149.3, 143.9, 135.0, 130.4, 129.7, 129.1, 128.5, 126.2, 125.5, 121.6, 117.5, 115.1, 114.5, 101.3, 61.8,

55.3, 54.3, 30.0 ; HRMS (ESI TOF (+)) calcd for $[C_{28}H_{28}ClN_7O + H^+]$ 514.2117 found 514.2117.

4.4.8. $N^1-((1\text{-tert-butyl-}1H\text{-tetrazol-}5\text{-yl})(3,4\text{-dimethoxyphenyl)methyl})\text{-}N^4\text{-(7-chloroquinolin-4-yl)benzene-1,4-diamine (18)}$

Yellow solid; Yield: 80 %; mp 80-81 °C; IR (cm^{-1} , KBr): 3412, 3018, 1576, 1422, 1251; ^1H NMR (300 MHz, CDCl_3): δ = 8.46 (d, 1H, J = 5.3 Hz), 7.99 (d, 1H, J = 1.83 Hz), 7.82 (d, 1H, J = 8.9 Hz), 7.42 (dd, 1H, J = 1.9 Hz, J = 8.9 Hz), 7.11 (d, 2H, J = 8.5 Hz), 6.93 (s, 1H), 6.85-6.82 (m, 2H), 6.73 (d, 2H, J = 8.6 Hz), 6.62 (d, 1H, J = 5.3 Hz), 6.53 (s, 1H), 6.09 (d, 1H, J = 9.3 Hz), 4.92 (d, 1H, J = 9.2 Hz), 3.87 (s, 3H), 3.85 (s, 3H), 1.71 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ = 155.1, 151.3, 149.6, 149.4, 149.3, 149.0, 143.9, 135.0, 130.3, 130.1, 128.1, 126.1, 125.5, 121.6, 120.3, 117.4, 115.1, 111.1, 110.7, 101.2, 61.8, 55.9, 55.8, 54.7, 29.9 HRMS (ESI TOF (+)) calcd for $[C_{29}H_{30}ClN_7O_2 + H^+]$ 544.2222 found 544.2222.

4.4.9. $N^1-((1\text{-tert-butyl-}1H\text{-tetrazol-}5\text{-yl})(3,4,5\text{-trimethoxyphenyl)methyl})\text{-}N^4\text{-(7-chloroquinolin-4-yl)benzene-1,4-diamine (19)}$

Pale Yellow solid Yield: 74 %; mp 168-170 °C; IR (cm^{-1} , KBr): 3428, 3017, 1578, 1373, 1234, 1105, 848; ^1H NMR (300 MHz, CDCl_3): δ = 8.45 (d, 1H, J = 5.3 Hz), 7.98 (d, 1H, J = 2.0 Hz), 7.84 (d, 1H, J = 8.9 Hz), 7.41 (dd, 1H, J = 2.1 Hz, J = 8.9 Hz), 7.11 (d, 2H, J = 8.6 Hz), 6.62 (d, 2H, J = 5.3 Hz), 6.55 (s, 2H), 6.06 (d, 1H, J = 9.3 Hz), 4.91 (d, 1H, J = 9.3 Hz), 3.84 (s, 3H), 3.80 (s, 6H), 1.73 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ = 154.9, 153.7, 151.7, 149.4, 149.1, 143.9, 138.3, 135.0, 133.2, 130.6, 128.6, 126.1, 125.5, 121.3, 117.5, 115.2, 105.0, 101.3, 61.8, 60.8, 56.2, 55.1, 30.0 HRMS (ESI TOF (+)) calcd for $[C_{30}H_{32}ClN_7O_3 + H^+]$ 574.2328 found 574.2328.

4.4.10. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(4-chlorophenyl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**20**)

Yellow solid; Yield: 84 %; mp 128-130 °C; IR (cm⁻¹, KBr): 3435, 3019, 2927, 1576, 1374, 1215; ¹H NMR (300 MHz, CDCl₃): δ = 8.44 (d, 1H, *J* = 5.2 Hz), 7.98 (d, 1H, *J* = 1.6 Hz), 7.84 (d, 1H, *J* = 8.9 Hz), 7.41-7.30 (m, 5H), 7.12 (d, 2H, *J* = 8.5 Hz), 6.72 (d, 2H, *J* = 8.5 Hz), 6.61 (d, 1H, *J* = 5.3 Hz), 6.13 (d, 1H, *J* = 8.6 Hz), 4.93 (d, 1H, *J* = 8.6 Hz), 2.50 (br s, 1H), 1.62 (s, 9H); ¹³C NMR (75 MHz, CDCl₃) δ = 154.7, 151.3, 149.3, 149.0, 143.6, 136.3, 135.2, 134.8, 130.6, 129.4, 129.1, 128.3, 126.2, 125.7, 121.4, 117.4, 115.2, 101.3, 61.9, 54.1, 30.1, HRMS (ESI TOF (+)) calcd for [C₂₇H₂₅Cl₂N₇ + H⁺] 518.1621 found 518.1622.

4.4.11. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(3,4-dichlorophenyl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**21**)

Yellow solid; Yield: 82 %; mp 200-201 °C; IR (cm⁻¹, KBr): 3412, 3018, 1610, 1515, 1215; ¹H NMR (300 MHz, DMSO-*d*₆): δ = 10.82 (br s, 1H), 8.74 (d, 1H, *J* = 9.1 Hz), 8.43 (d, 1H, *J* = 6.9 Hz), 8.09 (s, 1H), 7.86 (s, 1H), 7.83 (d, 1H, *J* = 9.1 Hz), 7.70 (d, 1H, *J* = 8.3 Hz), 7.57 (d, 1H, *J* = 8.2 Hz), 7.35 (d, 1H, *J* = 8.6 Hz), 7.20 (d, 2H, *J* = 8.1 Hz), 6.89 (d, 2H, *J* = 8.2 Hz), 6.63 (d, 1H, *J* = 6.9 Hz), 6.37 (d, 1H, *J* = 8.7 Hz), 1.76 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ = 154.9, 154.2, 145.4, 143.2, 140.0, 139.2, 138.1, 130.9, 130.5, 130.4, 130.2, 128.4, 127.1, 126.6, 126.5, 125.8, 119.3, 115.6, 113.9, 100.03, 62.4, 50.7, 29.2; HRMS (ESI TOF (+)) calcd for [C₂₇H₂₄Cl₃N₇ + H⁺] 552.1232 found 552.1231.

4.4.12. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(4-fluorophenyl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**22**)

Yellow solid; Yield: 65 %; mp 110-112 °C; IR (cm⁻¹, KBr): 3258, 2989, 1574, 1515, 1230; ¹H NMR (300 MHz, CDCl₃): δ = 8.45 (d, 1H, *J* = 5.4 Hz), 7.99 (d, 1H, *J* = 1.7 Hz), 7.83 (d, 1H, *J* = 9.0 Hz), 7.42-7.33 (m, 3H), 7.12-7.05 (m, 4H), 6.73 (d, 2H, *J* = 8.6 Hz), 6.62 (d, 1H, *J* = 5.4 Hz), 6.14 (d, 1H, *J* = 8.7 Hz), 4.91 (d, 1H, *J* = 9.6 Hz), 2.11 (br s, 1H), 1.72 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ = 158.8, 155.4, 151.5, 149.6, 149.1, 144.4, 133.7, 130.7, 129.3, 129.0, 127.2, 125.7, 124.4, 124.2, 117.5, 113.9, 113.7, 100.3, 61.8, 55.0, 51.7, 29.3; HRMS (ESI TOF (+)) calcd for [C₂₇H₂₅ClFN₇ + H⁺] 502.1917 found 502.1918.

4.4.13. *N*¹-((4-bromophenyl)(1-*tert*-butyl-1*H*-tetrazol-5-yl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**23**)

Yellow solid; Yield: 84 %; mp : >240°C; IR (cm⁻¹, KBr): 3436, 3019, 1571, 1516; ¹H NMR (300 MHz, DMSO-*d*₆) δ = 10.88 (s, 1H), 8.76 (d, 1H, *J* = 8.9 Hz), 8.43 (d, 1H, *J* = 6.9 Hz), 8.11 (s, 1H), 7.84 (d, 1H, *J* = 9.1 Hz), 7.61-7.48 (m, 4H), 7.25 (d, 1H, *J* = 8.3 Hz), 7.18 (d, 2H, *J* = 7.9 Hz), 6.68 (d, 2H, *J* = 7.9 Hz), 6.62 (d, 1H, *J* = 6.8 Hz), 6.32 (d, 1H, *J* = 8.1 Hz), 1.74 (s, 9H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ = 154.5, 154.1, 145.2, 142.3, 138.5, 137.7, 137.6, 130.7, 129.8, 126.5, 126.0, 125.7, 125.6, 120.6, 118.5, 115.1, 113.3, 99.4, 61.7, 50.7, 28.7; HRMS (ESI TOF (+)) calcd for [C₂₇H₂₅BrClN₇ + H⁺] 562.1116 found 562.1116.

4.4.14. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(phenyl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**24**)

Yellow solid; Yield: 72 %; mp 112-114 °C; IR (cm⁻¹, KBr): 3433, 3020, 1575, 1517, 1216; ¹H NMR (300 MHz, CDCl₃): δ = 8.44 (d, 1H, *J* = 5.3 Hz), 7.98 (d, 1H, *J* = 1.8 Hz), 7.84 (d, 1H, *J* = 8.9 Hz), 7.39-7.36 (m, 6H), 7.10 (d, 2H, *J* = 8.5 Hz), 6.72 (d, 2H, *J* = 8.6 Hz), 6.61 (d, 1H, *J* = 5.3 Hz), 6.15 (d, 1H, *J* = 9.3 Hz), 4.95 (d, 1H, *J* = 9.3 Hz), 1.70 (s, 9H); ¹³C NMR (75 MHz,

CDCl_3) δ = 155.0, 151.6, 149.3, 149.2, 143.8, 137.7, 134.9, 130.4, 129.1, 128.8, 128.4, 127.7, 126.1, 125.5, 121.5, 117.5, 115.0, 101.3, 61.8, 54.8, 30.0; HRMS (ESI TOF (+)) calcd for $[\text{C}_{27}\text{H}_{26}\text{ClN}_7 + \text{H}^+]$ 484.2011 found 484.2012.

4.4.15. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(*p*-tolyl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**25**)

Yellow solid; Yield: 70 %; mp 128-130 °C; IR (cm^{-1} , KBr): 3431, 2921, 1577, 1248; ^1H NMR (300 MHz, CDCl_3) δ = 8.45 (d, 1H, J = 4.9 Hz), 7.98 (s, 1H), 7.82 (d, 1H, J = 9.1 Hz), 7.41 (d, 1H, J = 8.6 Hz), 7.22 (d, 4H, J = 5.7 Hz), 7.10 (d, 2H, J = 7.9 Hz), 6.71 (d, 2H, J = 7.8 Hz), 6.62 (d, 1H, J = 4.9 Hz), 6.56 (s, 1H), 6.11 (d, 1H, J = 9.1 Hz), 4.91 (d, 1H, J = 9.5 Hz), 2.34 (s, 3H), 1.69 (s, 9H); ^{13}C NMR (75 MHz, CDCl_3) δ = 155.2, 151.6, 149.3, 143.9, 138.7, 134.9, 134.8, 130.3, 129.8, 128.4, 127.6, 126.1, 125.4, 121.5, 117.5, 115.0, 101.2, 61.8, 54.6, 29.9, 21.0 ; HRMS (ESI TOF (+)) calcd for $[\text{C}_{28}\text{H}_{28}\text{ClN}_7 + \text{H}^+]$ 498.2167 found 498.2174.

4.4.16. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl)(4-ethylphenyl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**26**)

Yellow solid; Yield: 74 %; mp 136-138°C; IR (cm^{-1} , KBr): 3455, 2956, 1564, 1248; ^1H NMR (300 MHz, $\text{DMSO}-d_6$): δ = 8.42 (d, 1H, J = 5.3 Hz), 8.01 (s, 1H), 7.90 (d, 1H, J = 8.9 Hz), 7.42 (d, 1H, J = 7.4 Hz), 7.28-7.21 (m, 5H), 7.14 (d, 2H, J = 8.3 Hz), 6.73 (d, 2H, J = 8.3 Hz), 6.62 (d, 1H, J = 5.3 Hz), 6.14 (d, 1H, J = 8.3 Hz), 4.94 (d, 1H, J = 8.0 Hz), 2.70 (q, 2H, J = 7.5 Hz), 1.71(s, 9H), 1.27-1.21 (m, 3H); ^{13}C NMR (50 MHz, CDCl_3) δ = 155.2, 150.9, 149.6, 148.6, 145.1, 144.1, 135.4, 134.9, 130.2, 128.7, 127.8, 126.1, 125.7, 121.7, 117.3, 115.1, 101.2, 61.8, 54.6, 30.1, 28.4, 15.3; HRMS (ESI TOF (+)) calcd for $[\text{C}_{29}\text{H}_{30}\text{ClN}_7 + \text{H}^+]$ 512.2324 found 512.2327.

4.4.17. *N*¹-((1-*tert*-butyl-1*H*-tetrazol-5-yl))(naphthalen-1-yl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**27**)

Yellow solid; Yield: 74 %; mp 140-142 °C; IR (cm⁻¹, KBr): 3358, 2933, 1573, 1375; ¹H NMR (300 MHz, CDCl₃): δ = 8.49 (d, 1H, *J* = 5.3 Hz), 8.14 (d, 1H, *J* = 8.2 Hz), 8.00 (d, 1H, *J* = 1.7 Hz), 7.97 (d, 1H, *J* = 7.9 Hz), 7.91 (d, 1H, *J* = 8.1 Hz), 7.84 (d, 1H, *J* = 9.0 Hz), 7.67-7.57 (m, 2H), 7.43-7.36 (m, 2H), 7.14 (d, 2H, *J* = 8.5 Hz), 6.92-6.86 (m, 2H), 6.77 (d, 2H, *J* = 8.5 Hz), 6.68 (d, 1H, *J* = 5.3 Hz), 6.54 (s, 1H), 4.79 (d, 1H, *J* = 9.7 Hz), 1.59 (s, 9H); ¹³C NMR (50 MHz, DMSO-*d*₆) δ = 154.9, 151.6, 149.5, 149.2, 144.4, 133.8, 133.7, 133.5, 130.6, 129.1, 128.7, 127.4, 126.8, 125.9, 125.3, 124.4, 124.1, 122.9, 117.6, 113.6, 100.4, 62.3, 49.7, 29.9; HRMS (ESI TOF (+)) calcd for [C₃₁H₂₈ClN₇ + H⁺] 534.2167 found 534.2167.

4.4.18. *N*¹-(7-chloroquinolin-4-yl)-*N*⁴-((1-cyclohexyl-1*H*-tetrazol-5-yl)(3,4-dimethoxyphenyl)methyl)benzene-1,4-diamine (**28**)

Yellow solid; Yield: 76 %; mp 138-140 °C; IR (cm⁻¹, KBr): 3432, 2933, 1634, 1516, 1254; ¹H NMR (300 MHz, CDCl₃): δ = 8.43 (d, 1H, *J* = 5.3 Hz), 7.97 (d, 1H, *J* = 1.8 Hz), 7.85 (d, 1H, *J* = 8.9 Hz), 7.40 (dd, 1H, *J* = 1.8 Hz, *J* = 8.9 Hz), 7.10 (d, 2H, *J* = 8.5 Hz), 6.97-6.84 (m, 3H), 6.73 (d, 2H, *J* = 8.6 Hz), 6.59 (d, 1H, *J* = 5.3 Hz), 5.82 (d, 1H, *J* = 5.9 Hz), 5.18 (d, 1H, *J* = 5.9 Hz), 4.30-4.23 (m, 1H), 3.87 (s, 3H), 3.83 (s, 3H), 2.09-1.95 (m, 5H), 1.83-1.72 (m, 3H), 1.37-1.29 (m, 3H); ¹³C NMR (100 MHz, CDCl₃+DMSO-*d*₆) δ = 154.2, 151.1, 149.5, 149.3, 149.0, 143.7, 134.5, 130.1, 129.6, 127.7, 125.9, 124.9, 122.4, 119.4, 117.4, 114.4, 110.8, 109.9, 100.6, 57.9, 55.7, 55.6, 53.2, 32.0, 25.0, 24.9, 24.3; HRMS (ESI TOF (+)) calcd for [C₃₁H₃₂ClN₇O₂ + H⁺] 570.2379 found 570.2372.

4.4.19. *N*¹-((4-chlorophenyl)(1-cyclohexyl-1*H*-tetrazol-5-yl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**29**)

Pale yellow solid; Yield: 76 %; mp 206 -208 °C; IR (cm⁻¹, KBr): 3480, 2933, 1574, 1517,1247; ¹H NMR (300 MHz, CDCl₃): δ = 8.45 (d, 1H, *J* = 7.2 Hz), 7.98 (s, 1H), 7.84 (d, 1H, *J* = 10.1 Hz), 7.37 (s, 5H), 7.11 (d, 1H, *J* = 9.2 Hz), 6.72-6.67 (m, 3H), 6.60 (d, 1H, *J* = 5.7 Hz), 5.87 (d, 1H, *J* = 7.5 Hz), 5.18 (d, 1H, *J* = 6.8 Hz), 4.27-4.20 (m, 1H), 2.07-1.75 (m, 8H), 1.45-1.28 (m, 2H); ¹³C NMR (75MHz, DMSO- *d*₆) δ = 154.7, 151.7, 149.5, 149.4, 144.2, 137.5, 133.6, 132.6, 129.6, 129.4, 128.5, 127.5, 125.8, 124.4, 124.1, 117.6, 114.0, 100.3, 56.9, 50.2, 32.5, 32.4, 24.7, 24.6, 24.4; HRMS (ESI TOF (+)) calcd for [C₂₉H₂₇Cl₂N₇ + H⁺] 544.1778 found 544.1738.

4.4.20 *N*¹-((4-bromophenyl)(1-cyclohexyl-1H-tetrazol-5-yl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**30**)

Yellow solid; Yield: 80 %; mp 208-209 °C; IR (cm⁻¹, KBr): 3358, 2933, 1573, 1315; ¹H NMR (300 MHz, CDCl₃): δ = 8.96 (d, 1H, *J* = 5.1 Hz), 8.68 (d, 1H, *J* = 8.7 Hz), 8.49 (s, 1H), 8.37 (br s, 1H), 8.11 (d, 2H, *J* = 7.5 Hz), 7.94-7.90 (m, 3H), 7.69 (d, 2H, *J* = 8.2 Hz), 7.32 (d, 2H, *J* = 8.2 Hz), 7.17 (d, 1H, *J* = 5.6 Hz), 6.53 (d, 1H, *J* = 6.3 Hz), 6.29 (d, 1H, *J* = 7.1 Hz), 4.95-4.87 (m, 1H), 2.31-2.16 (m, 4H), 1.86-1.82 (m, 6H); ¹³C NMR (75 MHz, DMSO-*d*₆) δ = 154.6, 151.5, 149.6, 149.2, 144.2, 137.9, 133.7, 131.4, 129.9, 129.3, 127.3, 125.8, 124.4, 124.1, 121.2, 117.6, 114.0, 100.3, 56.9, 50.3, 32.5, 32.3, 24.7, 24.6, 24.4; HRMS (ESI TOF (+)) calcd for [C₂₉H₂₇BrClN₇ + H⁺] 583.1273 found 583.1271.

4.4.21 *N*¹-((1-tert-butyl-1H-tetrazol-5-yl)(ferrocenyl)methyl)-*N*⁴-(7-chloroquinolin-4-yl)benzene-1,4-diamine (**31**)

Yellow solid; Yield: 86 %; mp 118 - 120 °C; IR (cm⁻¹, KBr): 3437, 3020, 1610, 1575,1216; ¹H NMR (300 MHz, CDCl₃): δ = 8.47 (d, 1H, *J* = 5.2 Hz), 7.99 (s, 1H), 7.86 (d, 1H *J* = 8.9 Hz), 7.41 (d, 1H, *J* = 8.3 Hz), 7.14 (d, 2H, *J* = 8.3 Hz), 6.76 (d, 2H, *J* = 8.3 Hz), 6.67 (br s, 1H), 6.63 (d, 1H, *J* = 5.2 Hz), 5.83 (d, 1H, *J* = 9.7 Hz), 5.06 (d, 1H, *J* = 9.7 Hz), 4.48 (s, 1H), 4.28 (s, 6H),

4.17 (s, 1H), 3.60 (s, 1H), 1.76 (s, 9H); ^{13}C NMR (50 MHz, CDCl_3) δ = 155.6, 151.5, 149.4, 149.1, 144.3, 135.2, 130.5, 128.3, 126.3, 125.6, 121.5, 117.5, 115.6, 101.3, 89.8, 69.1, 68.6, 68.1, 67.6, 67.2, 61.9, 49.6, 30.4; HRMS (ESI TOF (+)) calcd for $[\text{C}_{31}\text{H}_{30}\text{ClFeN}_7 + \text{H}^+]$ 592.1673 found 592.1677.

4.4.21 N^1 -((1-tert-butyl-1H-tetrazol-5-yl)(phenyl)methyl)- N^2 -(7-chloroquinolin-4-yl)ethane-1,2-diamine (**32**)

Yellow solid; Yield: 84 %; mp 120-121 °C; IR (cm^{-1} , KBr): 3435, 2928, 1636, 1583, 1334; ^1H NMR (300 MHz, CDCl_3): δ = 8.54 (d, 1H, J = 5.1 Hz), 8.03 (d, 1H, J = 8.9 Hz), 7.96 (s, 1H), 7.47 (d, 1H, J = 8.5 Hz), 6.42 (d, 1H, J = 4.8 Hz), 6.11 (s, 1H), 5.06 (s, 1H), 4.52 (s, 1H), 4.24 (s, 1H), 4.11 (s, 6H), 3.54 (s, 1H), 3.40-3.34 (m, 2H), 3.05-2.85 (m, 2H), 1.73 (s, 9H); ^{13}C NMR (50 MHz, CDCl_3) δ = 156.4, 151.9, 150.0, 148.9, 134.9, 128.5, 125.5, 121.6, 117.4, 99.1, 89.2, 68.9, 68.6, 68.2, 67.4, 67.1, 61.6, 52.8, 45.3, 42.5, 30.3; HRMS (ESI) calcd for $[\text{C}_{27}\text{H}_{30}\text{ClFeN}_7 + \text{H}^+]$ 544.1673; found 544.1679.

4.5 Bioevaluation methods:

4.5.1. In vitro antimalarial assay

The compounds were evaluated for antimalarial activity against 3D7 (CQ-sensitive) and K1 (CQ-resistant) strains of *Plasmodium falciparum* using Malaria SYBR Green I nucleic acid staining dye based fluorescence (MSF) assay as mentioned by Singh et al (2011) [38]. The stock (5mg/ml) solution was prepared in DMSO and test dilutions were prepared in culture medium (RPMI-1640-FBS). Chloroquine-diphosphate was used as reference drug.

4.5.1.1 Test Technique -

50µl of culture medium was dispensed in 96 well plate followed by addition of 50µl of highest concentration of test compounds (in duplicate wells) in row B. Subsequent two-fold serial dilutions were prepared and finally 50 µl of 1.0% parasitized cell suspension containing 0.8% parasitaemia was added to each well except 4 wells in row 'A' received non parasitized erythrocyte suspension. The plates were incubated at 37 °C in CO₂ incubator in an atmosphere of 5% CO₂ and air mixture and 72 hours later 100 µl of lysis buffer containing 2x concentration of SYBR Green-I (In Nitrogen) was added to each well and incubated for one hour at 37 °C. The plates were examined at 485±20nm of excitation and 530±20nm of emission for relative fluorescence units (RFUs) per well using the fluorescence plate reader (FLX800, BIOTEK)

4.5.1.2 Statistical analysis- Data was transferred into a graphic programme (EXCEL) and IC₅₀ values were obtained by Logit regression analysis of dose response curves using pre-programmed Excel spreadsheet

4.5.2. In vitro assay for evaluation of cytotoxic activity

Cytotoxicity of the compounds was carried out using Vero cell line (C1008; Monkey kidney fibroblast) following the method as mentioned in Sashidhara et al. (2012) [39]. The cells were incubated with compound-dilutions for 72h and MTT was used as reagent for detection of cytotoxicity. 50% cytotoxic concentration (CC₅₀) was determined using nonlinear regression analysis of dose response curves using pre-programmed Excel spreadsheet. Selectivity Index (SI) was calculated as

$$SI = CC_{50} / IC_{50}$$

4.5.3. In vitro assay for evaluation of β-hematin inhibition

Inhibition of *in vitro* β-hematin formation was analysed by using the method of Pandey *et al* (1999) with some modifications [40]. Male swiss albino mice, weighing 15-20g were inoculated with 1 x 10⁵ *P. yoelii* infected RBCs. Blood of infected animal at 50% parasitemia was collected

by cardiac puncture in 2.0% citrate buffer and centrifuged at 5000 rpm for 10 min at 4 °C. The plasma was used in assay of β -hematin formation. The assay mixture contained 100 mM sodium acetate buffer pH (5.1), 50 μ L plasma, 100 μ M hemin as the substrate and 1-20 μ g compound/drug in a total reaction volume of 1.0 mL. The control tubes contained all reagents except compound. The reaction mixture in triplicate was incubated at 37 °C for 16 h in a rotary shaker. The reaction was stopped by centrifugation at 10,000 rpm for 10 min at 30°C. The pellet was suspended in 100 mM Tris-HCl buffer pH (7.4) containing 2.5% SDS. The pellet obtained after centrifugation was washed thrice with distilled water (TDW) to remove free heme attached to β -hematin. The pellet was solubilized in 50 μ L of 2N NaOH and volume was made up to 1.0 mL with TDW. Absorbance was measured at 400 nm. The 50% inhibitory concentration (IC_{50}) was determined using non-linear regression analysis of dose response curves.

4.5.4 *In vivo antimalarial assay*

The *in vivo* drug response was evaluated in Swiss mice infected with *P. yoelii* (N-67 strain) which is innately resistant to CQ [41]. The mice (22 $\pm$ 2g) were inoculated with 1×10^6 parasitized RBC on day 0 and treatment was administered to a group of five mice from day 0-3, once daily. The aqueous suspensions of compounds were prepared with a few drops of Tween 80. Initially, the efficacy of test compounds was evaluated at 50.0 mg/kg/day and required daily dose was administered in 0.2 mL volume *via* intraperitoneal route. The efficacy of test compounds was evaluated at 100 mg/kg/day and required daily dose was administered in 0.1 mL volume *via* oral route. Parasitemia levels were recorded from thin blood smears between days 4 and 6. The mean value determined for a group of 5 mice was used to calculate the percent suppression of parasitemia with respect to the untreated control group. Mice treated with CQ served as reference controls.

4.5.5 *Pharmacokinetic Evaluation.*

The pharmacokinetic studies of compounds **20** and **23** were carried out in young and healthy male Sprague-Dawley rats weighing 250 ± 25 g. The rats were obtained from Laboratory Animal Division of the Institute and were housed in plastic cages under standard laboratory conditions with a regular 12 h day-night cycle. Standard pelleted laboratory chow (Goldmohar Laboratory Animal Feed, Lipton India Ltd, Chandigarh, India) and water were allowed *ad libitum*. The rats were acclimatized to this environment for at least two days before conducting the experiments. In all the studies mentioned below the dose was administered after overnight fasting (12-16 h). The study was conducted in three rats per time point. In all experiments, euthanasia and disposal of carcasses were carried out as per the guidelines of Local Ethics Committee for animal experimentation.

Suspension formulation of the compounds were separately prepared by triturating the compound with gum acacia and water in a pestle with mortar, and a single oral dose of 10 mg/Kg was given to conscious rats by oral gavage in a volume of approximately 1 mL/250 g rat and the time of dosing was recorded. Rodent food and water were provided 2 h after the dose. Blood samples were collected at 0.5, 1, 1.5, 2, 4, 6, 8, 10, 18, and 24 h post dose. Two blood samples were withdrawn from each animal. An initial 1.5 mL blood sample was drawn by cardiac puncture under light anesthesia followed by a sample drawn from the inferior vena cava (terminal sample), from the dosed rats using a 24G needle and a syringe in a clean and dry test tube. The total volume of blood collected from each rat was not more than 3% of the total body volume. The blood was allowed to clot, by keeping the tube on a slant, approximately for 45 min. Then it was centrifuged at 2000 rpm for 10 min and the serum was separated into clean and neatly labeled tubes. All samples were stored at -20°C until analysis.

Chromatographic separations and quantification of the compounds was achieved by a reverse phase HPLC method on a Discovery HS C-18 column ($5\text{ }\mu\text{m}$, $100 \times 4.6\text{ mm id}$) preceded

with a guard column (5 μ m, 20 x 4.0 mm, id) packed with the same material under isocratic condition at a flow rate of 1 mL/min. The HPLC system used in this study consisted of a pump (LC-10AT VP with FCV-10AL VP), degasser (DGU-14A) and auto-injector (SIL-HTc, fixed with a 100 μ l loop) (Shimadzu, Japan). Eluents were monitored at 253 nm for **20** and 257 nm for **23** with UV-Vis multiple wavelength detector (Shimadzu, Japan) and chromatograms were integrated using Class-VP (version 6.12 SP5) software. The mobile phase composition was 0.01 M aqueous ammonium acetate : acetonitrile (35:65, v/v) and it was degassed by ultrasonication for 15 min before use. The HPLC system was equilibrated for approximately 30 min before commencement of analysis and chromatography was carried out at ambient temperature. The lower limit of quantification for the analytical method was 10 ng/mL of test analyte in serum. The mean and SEM of the serum concentrations of the candidate drug at each time point was calculated using Microsoft Excel for Windows. All pharmacokinetic parameters were calculated by noncompartmental models using WinNonlin program, version 5.1 (Scientific Consulting Inc.).

Acknowledgments

SP is thankful to University Grant Commission, New Delhi, for financial support in the form of SRF, SAIF-CDRI Lucknow for providing spectral and analytical data and Mrs. Rima Ray Sarkar for technical support in β -Hematin inhibitory activity evaluation.

References and notes

- [1] WHO. World Malaria Report 2011 (WHO, Geneva, Switzerland, 2011).
- [2] P. M. S. Chauhan, S. K. Srivastava, Curr. Med. Chem. 8 (2001) 1535-1542.
- [3] U. Frevert, Trend Parasitol. 20 (2004) 417-424.
- [4] C. Wongsrichanalai, S. R. Meshnick, Emerg. Infect. Dis. 14 (2008) 716-719.
- [5] M. Schlitzer, Curr. Med. Chem. 22 (2007) 944-986.

- [6] C. O'Brien, P. P. Henrich, N. Passi, D. A. Fidock, *Curr. Opin. Infect. Dis.* 24 (2011) 570–577.
- [7] S. R. Hawley, P. G. Bray, M. Mungthin, J. D. Atkinson, P. M. O' Neill, S. A. Ward, *Antimicrob. Agents Chemother.* 42 (1998) 682-686.
- [8] R. G. Ridley, *Nature*, 374 (1995) 269–271.
- [9] J. Y. Hwang, T. Kawasuji, D. J. Lowes, J. A. Clark, M. C. Connelly, F. Zhu, W. A. Guiguemde, M. S. Sigal, E. B. Wilson, J. L. DeRisi, R. K. Guy, *J. Med. Chem.* 54 (2011) 7084-7093.
- [10] P. B. Madrid, A. P. Liou, J. L. DeRisi, R. K. Guy, *J. Med. Chem.* 49 (2006) 4535-4543.
- [11] K. A. Ekoue-Kovi, K. Yearick, D. P. Iwaniuk, J. K. Natarajan, J. Alumasa, A. C. de Dios, P. D. Roepe, C. Wolf *Bioorg. Med. Chem.* 17 (2009) 270-283.
- [12] J. K. Natarajan, J. N. Alumasa, K. Yearick, K. A. Ekoue-Kovi, L. B. Casabianca, A. C. de Rios, C. Wolf, P. D. Roepe, *J. Med. Chem.* 51 (2008) 3466-3479.
- [13] O. Dechy-Cabaret, F. Benoit-Vical, C. Loup, A. Robert, H. Gornitzka, A. Bonhoure, H. Vial, J. F. Magnaval, J. P. Seguela, B. Meunier, *Chemistry* 10 (2004) 1625-1636.
- [14] F. Bellot, F. Cosledan, L. Vendier, J. Brocard, B. Meunier, A. Robert, *J. Med. Chem.* 53 (2010) 4103-4109.
- [15] A. Kumar, K. Srivastava, S. R. Kumar, M. I. Siddiqi, S. K. Puri, J. K. Saxena, P. M. S. Chauhan, *Eur. J. Med. Chem.* 46 (2011) 676-690.
- [16] S. Manohar, U. C. Rajesh, S. I. Khan, B. L. Tekwani, D. S. Rawat, *ACS Med. Chem. Lett.* 3 (2012) 555-559.
- [17] E. M. Guantai, K. Ncokazi, T. J. Egan, J. Gut, P. J. Rosenthal, R. Bhampidipati, A. Kopinathan, P. J. Smith, K. Chibale, *J. Med. Chem.* 54 (2011) 3637-3649.

- [18] S. Gemma, G. Campiani, S. Butini, G. Kukreja, S.S. Coccone, B. P. Joshi, M. Persico, V. Nacci, I. Fiorini, E. Novellino, E. Fattorusso, O. Taglialatela-Scafati, L. Savini, D. Taramelli, N. Basilico, S. Parapini, G. Morace, V. Yardley, S. Croft, M. Coletta, S. Marini, C. Fattorusso, *J. Med. Chem.* 51 (2008) 1278–1294.
- [19] S. Gemma, G. Campiani, S. Butini, B. P. Joshi, G. Kukreja, S. S. Coccone, M. Bernetti, M. Persico, V. Nacci, I. Fiorini, E. Novellino, D. Taramelli, N. Basilico, S. Parapini, V. Yardley, S. Croft, S. Keller- Maerki, M. Rottmann, R. Brun, M. Coletta, S. Marini, G. Guiso, S. Caccia, C. Fattorusso, *J. Med. Chem.* 52 (2009) 502–513.
- [20] E. S. Schaffert, G. Höfner, K. T. Wanner *Bioorg. Med. Chem.* 19 (2011) 6492–6504.
- [21] X. Li, Z. Tu, H. Li, C. Liu, Z. Li, Q. Sun, Y. Yao, J. Liu, S. Jiang, *ACS Med. Chem. Lett.* 4 (2013) 132–136.
- [22] K. Raman, S. S. Parmar, S. P. Singh, *J. Heterocyclic Chem.* 17 (1980) 1137–1139.
- [23] J. R. Maxwell, D. A. Wasdahl, A.C. Wolfson, V. I. Stenberg *J. Med. Chem.* 27 (1984) 1565–1570.
- [24] N. P. Peet, L. E. Baugh, S. Sundler, J. E. Lewis, E. H. Matthews, E. L. Olberding, D. N. Shah, *J. Med. Chem.* 29 (1986) 2403–2409.
- [25] L. M. T Frija, R. Fausto, R. M. S. Loureiro, M. L. S. Cristiano, *J. Mol. Cat. A Chem.* 305 (2009) 142–146.
- [26] G. Roman, M.N. Rahman, D. Vukomanovic, Z. Jia, K. Nakatsu, W.A. Szarek, *Chem. Biol. Drug Des.* 75 (2010) 68–90.
- [27] M. Sharma, K. Chauhan, S. S. Chauhan, A. Kumar, S. V. Singh, J. K. Saxena, P. Agarwal, K. Srivastava, S. R. Kumar, S. K. Puri, P. Shah, M. I. Siddiqi, P. M. S. Chauhan, *Med. Chem. Commun.* 3 (2012) 71–79.

- [28] N. Sunduru, M. Sharma, K. Srivastava, S. Rajakumar, S. K. Puri, J. K. Saxena, P. M. S. Chauhan, *Bioorg. Med. Chem.* 17 (2009) 6451-6462.
- [29] A. Kumar, K. Srivastava, S. Rajakumar, S. K. Puri, P. M. S. Chauhan, *Bioorg. Med. Chem. Lett.* 20 (2010) 7059-7063.
- [30] K. Chauhan, M. Sharma, J. Saxena, S. V. Singh, P. Trivedi, K. Srivastava, S. K. Puri, J. K. Saxena, V. Chaturvedi, P. M. S. Chauhan, *Eur. J. Med. Chem* (just accepted).
- [31] C. Biot, W. Daher, C. M. Ndiaye, P. Melnyk, B. Pradines, N. Chavain, A. Pellet, L. Fraisse, L. Pelinski, C. Jarry, X. J. Brocard, J. Khalife, I. F. Bares, D. Dive, *J. Med. Chem.* 49 (2006) 4707-4714;
- [32] F. Dubar, G. Anquetin, B. Pradines, D. Dive, J. Khalife, C. Biot, *J. Med. Chem.* 52 (2009) 7954–7957;
- [33] F. Bellot, F. Cosledan, L. Vendier, J. Brocard, B. Meunier, A. Robert, *J. Med. Chem.* 53 (2010) 4103–4109.
- [34] M. Patra, K. Ingram, V. Pierroz, S. Ferrari, B. Spingler, J. Keiser, G. Gasse, *J. Med. Chem.* 55 (2012) 8790–8798.
- [35] K. R. Godfrey, P. A. Arunde, Z. Dong, R. Bryant, *Comput Methods Programs Biomed* 104 (2011) 62-69.
- [36] B. Davies, T. Morris, *Pharm Res* 10 (1993) 1093-1095.
- [37] K.B. Mustapha, M. T. Bakare-odunola, M. Garba, O. O. Obodozie, I. S. Enemali, U. S. Inyan, *Eur. J. Drug Metabol. Pharmacokinet.* 34 (2009) 151-155.
- [38] S Singh, R. K. Srivastava, M. Srivastava, S. K. Puri and K. Srivastava, *Exptl. Parasitol.* 127 (2011) 318-321.

- [39] K.V. Sashidhara, M. Kumar, R. K. Modukuri, R. K. Srivastava, A. Soni, K. Srivastava, S. V. Singh, J. K. Saxena, H. M. Gauniyal, S. K. Puri, Bioorg. Med.Chem. 20 (2012) 2971-2981.
- [40] A.V. Pandey, N. Singh, B. L. Tekwani, S. K. Puri, V. S. Chauhan, J. Pharm. Biomed. Anal. 20 (1999) 203-207.
- [41] S. K. Puri, N. Singh, Exp. Parasitol 94 (2000) 8-14.

Captions:

Table 1 *In vitro* antimalarial activity of compounds against 3D7 and K1 strains of *P. falciparum* and their cytotoxicity against VERO cell line

Table 2 β -Hematin inhibitory activity of selected compounds.

Table 3 *In vivo* antimalarial activity of selected compounds against CQ resistant N-67 strain of in swiss mice.

Table 4. **Table 4.** Pharmacokinetic parameters of **20**, **23** and **CQ** in male rats.

Figure 1. Structures of some 4-aminoquinoline derivatives with antimalarial activity.






Figure 2 Basis for the synthesis of tetrazole derivatives of 4-aminoquinoline .






Figure 3 Concentration-time profile of **20** and **23** after a single oral (10 mg/kg) dose in male Sprague-Dawley rats. Bar represents SEM







Scheme 1 Synthesis of 4-aminoquinoline-tetrazole derivatives.



Table 1 *In vitro* antimalarial activity of compounds against 3D7 and K1 strains of *P. falciparum* and their cytotoxicity against VERO cell line

Compound no.	Structure	^a <i>In vitro</i> antimalarial activity IC ₅₀ (nM)		^b SI	^c Log P	^d RI
		3D7	K1			
11		23.89	277.80	839.68	4.99	11.6
12		120.40	184.40	305.32	5.47	1.5
13		81.40	754.50	248.65	5.26	9.2
14		216.10	170.20	58.67	5.75	0.8
15		57.88	137.50	1662.92	4.23	2.3

16		786.9	159.00	182.96	5.34	0.2
17		57.66	383.50	702.34	6.58	6.6
18		70.58	76.16	193.28	6.17	1.0
19		54.22	572.80	300.57	6.15	10.5
20		10.66	142.9	4616.14	7.02	13.4

21		11.01	141.90	7076.29	7.81	12.8
22		29.52	669.30	3165.31	6.66	22.67
23		11.78	233.7	2332.43	7.33	19.8
24		59.64	>1023	2383.47	6.52	-
25		1006	75.39	-	6.97	0.07

26		51.35	688.30	3652.19	7.44	13.4
27		28.00	77.79	3815.38	7.68	2.7
28		853.40	144.40	49.73	6.89	0.1
29		156.40	138.60	694.18	7.92	0.9
30		92.66	73.70	1191.58	8.05	0.8
31		585.83	>1000	261.70	-	-

32		>1000	>1000	48.77	-	-
CQ		5.4 ± 0.98	254 ± 20.65	8983.00	5.00	47.03

^a IC₅₀ (nM): concentration corresponding to 50% growth inhibition of the parasite. ^b Selectivity index (SI): (IC₅₀ values of cytotoxic activity/IC₅₀ values of antimalarial activity). ^c log P values calculated using on line software www.molinspiration.com, ^dResistance index (IC₅₀-K1/ IC₅₀-3D7).

Table 2 β -Hematin inhibitory activity of selected compounds^a

Compound No.	IC ₅₀ (μg/mL)	Compound No.	IC ₅₀ (μg/mL)
11	6.15	23	5.65
12	6.33	24	5.55
13	5.95	25	5.39
14	4.45	26	5.95
15	5.50	27	5.12
16	5.32	28	5.19
17	5.55	29	3.81
18	5.42	30	4.38
19	5.65	31	4.55
20	5.29	32	6.32
21	5.40	CQ	3.95
22	5.49		

^aThe IC₅₀ represents the concentration of compound that inhibits β -hematin formation by 50%.

Data are the mean of three different experiments in triplicate.

Table 3 *In vivo* antimalarial activity of selected compounds against CQ resistant N-67 strain of in swiss mice.

Compound code	Dose (mg/kg x 4 days)	Route of administration	Percent suppression on Day 4 post infection	Survival ^a	MST ^b	Cure ^c
16	50	IP	73.91	0/5	13.00±1.58	0/5
18	50	IP	26.91	0/5	9.80±1.02	0/5
20	50	IP	99.99	3/5	23.60±2.71	3/5
20	100	Oral	99.99	3/5	25.2±1.74	3/5
21	50	IP	71.49	0/5	16.83±1.83	0/5
23	50	IP	99.99	4/5	26.00±2.00	2/5
23	100	Oral	99.99	3/5	25.60±1.47	2/5
25	50	IP	21.30	0/5	11.00±1.23	0/5
27	50	IP	57.03	0/5	12.00±0.55	0/5
29	50	IP	20.43	0/5	10.40±1.21	0/5
30	50	IP	69.56	0/5	12.60±1.5	0/5
Control	-	IP	-	-	9.6±1.20	0/5
CQ	10	Oral	99.99	0/5	16.5±1.40	0/5

^aNumber of mice that survived till day 28 postinfection/total mice in the group. ^bMST, mean survival time (days) ± standard error(SE). ^cNumber of mice without parasitaemia (cured) till day 28 postinfection

Table 4. Pharmacokinetic parameters of **20**, **23** and **CQ** in male rats.

Parameters		^a 20	^a 23	^b CQ
C_{max} (ng/ml)	1	49.20 ± 2.10	57.73 ± 4.88	5228.7
	2	52.44 ± 5.69	49.65 ± 0.94	
	3	-	44.42 ± 5.16	
t_{max} (h)	1	2	1.5	0.91
	2	6	4	
	3	-	8	

AUC _{0-t} (ng h/ml)	593.3	703.52	30147
t _{1/2} (h)	5.27	22.64	9.5
V _d (L)	28.16	63.38	1.49
Clearance (L/h)	3.70	1.94	0.15

^aEach value represents the average of three rats dosed orally (10 mg/kg); ^bEach value represents the average of six rats dosed orally (5 mg/kg); Values of C_{max} are mean ± SEM;

Abbreviations: AUC_{0-t} = area under the serum concentration-time curve up to last sampling time, C_{max} = serum peak concentration, t_{max} = time to C_{max}, t_{1/2} = elimination half-life, V_d = volume of distribution

Figures




Figure 1. Structures of some 4-aminoquinoline derivatives with antimalarial activity




Figure 2: Basis for the synthesis of tetrazole derivatives of 4-aminoquinoline





Figure 3. Concentration-time profile of **20** and **23** after a single oral (10 mg/kg) dose in male Sprague-Dawley rats. Bar represents SEM.

Schemes

Scheme 1 Synthesis of 4-aminoquinoline-tetrazole derivatives.



Reagents and Conditions: (a) diamines, 110 °C, neat or ethanol; (b) TMSN₃, MeOH, rt, 24 h.

Research highlights:

Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents

Shashi Pandey^a, Pooja Agarwal^b, Kumkum Srivastava^b, S. RajaKumar^b, Sunil K. Puri^b, Pravesh Verma^c, J. K. Saxena^c, Abhisheak Sharma^d, Jawahar Lal^d and Prem. M. S. Chauhan^{a,*}

^a Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^b Parasitology Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^c Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^d Pharmacokinetics and Metabolism Division CSIR-Central Drug Research Institute, Lucknow 226001, India

- A series of 4-aminoquinoline-tetrazoles were synthesized via Ugi multicomponent reaction.
- Most of the compounds exhibited potent antimalarial activity against K1-strain.
- Compounds **20** and **23** found to be orally active against CQ-resistant strain of *P. yoelii*.
- *In vivo* oral pharmacokinetic study of compound **20** and **23** were also performed.
- Compound **20** and **23** could be worthy candidates for developing new antimalarials.

Supplementary data

Synthesis and bioevaluation of novel 4-aminoquinoline-tetrazole derivatives as potent antimalarial agents



Shashi Pandey^a, Pooja Agarwal^b, Kumkum Srivastava^b, S. RajaKumar^b, Sunil K. Puri^b, Pravesh Verma^c, J. K. Saxena^c, Abhisheak Sharma^d, Jawahar Lal^d and Prem. M. S. Chauhan^{a, *}



^a Medicinal and Process Chemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^b Parasitology Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,



^c Biochemistry Division, CSIR-Central Drug Research Institute, Lucknow 226001, India,

^d Pharmacokinetics and Metabolism Division CSIR-Central Drug Research Institute, Lucknow 226001, India


^1H NMR, ^{13}C NMR of compounds **^1H and ^{13}C Spectrum of compound **11****





¹H and ¹³C Spectrum of compound 12





¹H and ¹³C Spectrum of compound 13








¹H and ¹³C Spectrum of compound **16**





¹H and ¹³C Spectrum of compound 17





^1H and ^{13}C Spectrum of compound **18**





¹H and ¹³C Spectrum of compound **19**





¹H and ¹³C Spectrum of compound 20





¹H and ¹³C Spectrum of compound 21



¹H and ¹³C Spectrum of compound 22





¹H and ¹³C Spectrum of compound 23





¹H and ¹³C Spectrum of compound **24**

Chemical structure of compound 16 is shown above the spectrum. The structure is a 4-((4-chloroquinolin-2-yl)amino)-N-tert-butyl-1H-1,2,4-triazol-3-amine derivative. The spectrum displays the following chemical shifts (ppm): 8.4566, 8.4401, 7.9884, 7.8258, 7.7955, 7.4155, 7.3969, 7.2540, 7.2191, 7.1969, 7.1015, 7.0752, 6.7169, 6.6909, 6.6204, 6.6040, 6.5605, 6.1157, 6.0854, 4.9138, 4.8819, 2.3449, 1.6981, and 0.0731. Integration values are provided below the baseline: 1.08, 1.00, 1.09, 1.32, 3.89, 2.17, 2.04, 1.84, 0.97, 0.96, 3.34, 9.08, and 9.07.








¹H and ¹³C Spectrum of compound 29



¹H and ¹³C Spectrum of compound 30

¹H and ¹³C Spectrum of compound **31**



¹H and ¹³C Spectrum of compound 32